Post-Marketing Safety Data for Brexanolone (Zulresso)
In 2019, brexanolone (marketed by Sage Therapeutics as Zulresso) was approved by the FDA for the treatment of postpartum depression (PPD). Because preliminary studies indicated that brexanolone may have potentially serious side effects, including excessive sedation and sudden loss of